Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THR-317 + Ranibizumab in DME
NCT03499223Phase 2Completed
- Sponsor
- Oxurion
- Start
- Apr 2018
- Primary completion
- Jul 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of THR-317 in diabetic macular edema (DME), sponsored by Oxurion. Started Apr 2018; status: completed.
02
Drugs
THR-317
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT03499223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03499223.